» Articles » PMID: 19530164

Extracellular Matrix Produced by Bone Marrow Stromal Cells and by Their Derivative, SB623 Cells, Supports Neural Cell Growth

Overview
Journal J Neurosci Res
Specialty Neurology
Date 2009 Jun 17
PMID 19530164
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Several studies have shown the benefits of transplanting bone marrow-derived multipotent mesenchymal stromal cells (MSC) into neurodegenerative lesions of the central nervous system, despite a low engraftment rate and the poor persistence of grafts. It is known that the extracellular matrix (ECM) modulates neuritogenesis and glial growth, but little is known about effects of MSC-derived ECM on neural cells. In this study, we demonstrate in vitro that the ECM produced by MSC can support neural cell attachment and growth. We also compare the neurosupportive properties of MSC to the MSC derivative, SB623 cells, which is being developed as a cell therapy for stroke. Embryonic rat brain cortical cells cultured for 3 weeks on human MSC- and SB623 cell-derived ECM exhibit about a 1.5 and 3 times higher metabolic activity, respectively, compared with the cultures grown on poly-D-lysine (PDL), although the initial neural cell adhesion to cell-derived ECM and PDL is similar. The MSC- and SB623 cell-derived ECM protects neural cells from nutrient and growth factor deprivation. Under the conditions used, only neurons grow on PDL. In contrast, both MSC- and SB623 cell-derived ECMs support the growth of neurons, astrocytes, and oligodendrocytes, as demonstrated by immunostaining. Morphologically, neurons on cell-derived ECM form more complex and extended neurite networks than those cultured on PDL. Together, these data indicate that the beneficial effect of MSC and SB623 cells in neurotransplantation could be explained in part by the neurosupportive properties of the ECM produced by these cells.

Citing Articles

Modified human mesenchymal stromal/stem cells restore cortical excitability after focal ischemic stroke in rats.

Klein B, Ciesielska A, Losada P, Sato A, Shah-Morales S, Ford J Mol Ther. 2024; 33(1):375-400.

PMID: 39668560 PMC: 11764858. DOI: 10.1016/j.ymthe.2024.12.006.


Understanding the Pathophysiology of Ischemic Stroke: The Basis of Current Therapies and Opportunity for New Ones.

Salaudeen M, Bello N, Danraka R, Ammani M Biomolecules. 2024; 14(3).

PMID: 38540725 PMC: 10968326. DOI: 10.3390/biom14030305.


Synergistic therapeutic effects of intracerebral transplantation of human modified bone marrow-derived stromal cells (SB623) and voluntary exercise with running wheel in a rat model of ischemic stroke.

Yabuno S, Yasuhara T, Nagase T, Kawauchi S, Sugahara C, Okazaki Y Stem Cell Res Ther. 2023; 14(1):10.

PMID: 36691091 PMC: 9872315. DOI: 10.1186/s13287-023-03236-4.


Transplantation of modified human bone marrow-derived stromal cells affords therapeutic effects on cerebral ischemia in rats.

Kawauchi S, Yasuhara T, Kin K, Yabuno S, Sugahara C, Nagase T CNS Neurosci Ther. 2022; 28(12):1974-1985.

PMID: 36000240 PMC: 9627357. DOI: 10.1111/cns.13947.


Muse cells: ushering in a new era of stem cell-based therapy for stroke.

Li H, Wei J, Liu X, Zhang P, Lin J Stem Cell Res Ther. 2022; 13(1):421.

PMID: 35986359 PMC: 9389783. DOI: 10.1186/s13287-022-03126-1.